



ELSEVIER

Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib

Data Article

Data on *in vivo* selection of SK-OV-3 Luc ovarian cancer cells and intraperitoneal tumor formation with low inoculation numbersElly De Vlieghere^a, Charlotte Carlier^b, Wim Ceelen^b, Marc Bracke^{a,*}, Olivier De Wever^a^a Laboratory of Experimental Cancer Research, Ghent University, Belgium^b Laboratory of Experimental Surgery, Ghent University hospital, Belgium

ARTICLE INFO

Article history:

Received 10 November 2015

Received in revised form

15 December 2015

Accepted 28 December 2015

Available online 6 January 2016

Keywords:

in vivo selection

Ovarian cancer

Mouse model

Growth curves

Survival curves

ABSTRACT

This data paper contains information about the *in vivo* model for peritoneal implants used in the paper “Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells” (De Vlieghere et al., 2015) [1]. A double *in vivo* selection of SK-OV-3 Luc human ovarian cancer cell line was used to create SK-OV-3 Luc IP1 and SK-OV-3 Luc IP2 cell lines. This data paper shows functional activities of the three cell lines *in vitro* and *in vivo*. Phase-contrast images show the morphology of these cells, metabolic and luciferase activity has been determined. Survival data of mice peritoneally injected with SK-OV-3 Luc or SK-OV-3 Luc IP2 is available with H&E histology of the peritoneal implants. Tumor growth curves and bioluminescent images of mice inoculated with a different number of SK-OV-3 Luc IP2 cells are also included.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>).

Specifications table

Subject area	Biology
	Cancer biology

* Corresponding author.

E-mail addresses: Marc1.Bracke@UGent.be (M. Bracke), Olivier.dewever@ugent.be (O. De Wever).<http://dx.doi.org/10.1016/j.dib.2015.12.037>

2352-3409/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article as: E. De Vlieghere, et al., Data on *in vivo* selection of SK-OV-3 Luc ovarian cancer cells and intraperitoneal tumor formation with low inoculation numbers, Data in Brief (2016), <http://dx.doi.org/10.1016/j.dib.2015.12.037>

More specific sub- ject area	
Type of data	Phase contrast images, graphs, histology, bioluminescence images
How data was acquired	<ul style="list-style-type: none">• Phase contrast microscope (DMI 3000B, Leica, Wetzlar, Germany)• Plate reader (Paradigm, Molecular Devices, Sunnyvale, CA, USA)• Light microscope (DM750, Leica, Wetzlar, Germany)• Bioluminescent imager (IVIS, PerkinElmer, Waltham, MA, USA)
Data format	Analyzed
Experimental factors	SK-OV-3-Luc cells were inoculated intraperitoneally in immune deficient female mice Swiss/nu to select for a population that more efficiently forms peritoneal implants.
Experimental features	The created cell line SK-OV-3 Luc IP1 and SK-OV-3 Luc IP2 are compared with the parental cell line SK-OV-3 Luc
Data source location	Ghent, Belgium
Data accessibility	The data is available with this article

Value of the data

- This data shows intraperitoneal tumor formation with low cell inoculation after *in vivo* selection of SK-OV-3.
- This method can be applied to other cancer cell lines to increase metastasis take rate even with lower inoculation numbers.
- These data provides growth curves, survival data and histology about the SK-OV-3 Luc (IP2) *in vivo* model for peritoneal implants, providing researchers with a references for their *in vivo* studies.

1. Data

Intraperitoneal injection (IP) of SK-OV-3 (Luc) cells is an established *in vivo* model for the development of peritoneal ovarian tumor implants. Usually inoculation numbers of $1-2 \times 10^6$ SK-OV-3 (Luc) are used [2–4]. The IP injection of 1×10^6 SK-OV-3 Luc cells gives a 100% tumor take with an average survival time of over 2 months (Fig. 3B) [3]. To better mimic the patient situation where an initial low number of aggressive disseminated cells can form extensive peritoneal metastasis a xenograft mouse model with inoculation of low numbers of cancer cells is needed. *in vivo* selection has been successfully used to increase the metastatic potential of MDA-MB-231 [5]. These data describe the successive *in vivo* selection of the SK-OV-3 Luc cell line. Tumor implants of SK-OV-3 Luc bearing mice are re-cultured *in vitro* to increase *in vivo* peritoneal implant formation. After successive *in vivo* selection, IP inoculation of 10-to-20X lower number (1×10^5) of SK-OV-3 Luc IP2 is sufficient to form peritoneal implants this model has been applied successfully [1].

2. Experimental design, materials and methods

2.1. Cell culture conditions

SK-OV-3 is a human ovarian cancer cell line (ATCC number: HTB-77). SK-OV-3 Luc (Luciferase positive SK-OV-3 cells) were prepared by pFL4.76 plasmid transfection and selection (Promega, Leiden, The Netherlands). SK-OV-3 Luc (IP1/2) were maintained in Dulbecco's modified Eagle's medium

(DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin/streptomycin), and incubated at 37 °C with 10% CO₂ in air.

2.2. *in vivo* selection

Animal experiments were conducted accordance with the local ethics committee (Ghent University Hospital). 1×10^6 SK-OV-3-Luc cells were inoculated intraperitoneally in immunodeficient female Swiss/nu mice (Charles River, Chatillon-sur-Chalaronne, France) to isolate populations that form peritoneal implants. Tumor implants were collected in saline. The implants were cut into small pieces (1 mm) and dissociated by de gentleMACS Dissociator (Miltenyi Biotec, Teterow, Germany) in the presences of 1 mg/ml collagenase from *Clostridium histolyticum* (Sigma-Aldrich) in PBS^D⁺. The mixture was cleared through a cell strainer (70 µm) and the homogenized single cell suspension was expanded in culture by seeding in DMEM 10% FBS. After 24 h, non-adhered cells were removed and the medium was refreshed; the resulting culture was maintained as the parental cell line. Each subsequent intraperitoneal metastatic generation is designated IP1, IP2. Fig. 1 shows a schematic with the different stages of the *in vivo* selection. Fig. 2A shows phase-contrast images of the three cell lines cultured on plastic

2.3. Sort tandem repeat (SRT) profiling

SRT-profiling was conducted on the SK-OV-3, SK-OV-3 Luc and SK-OV-3 Luc IP2 cell lines to confirm the identity of the cell lines. 9 DNA sites were profiled and the alleles were identical between the three cell lines and to the profile published by ATCC (Amelogenin: X; CSF1PO: 11; D13S317: 8,11; D16S539: 12; D5S818: 11; D7S820: 13,14; TH01: 9,9,3; TPOX: 8,11; vWA: 17,18) [6].

2.4. Metabolic activity analysis: 3-4,5-Dimethylthiazolyl-2-2,5-Diphenyltetrazolium Bromide (MTT)

A single cell suspension of 4×10^4 SK-OV-3 Luc or SK-OV-3 Luc IP1 cells per well, were seeded in a 96-well plate. After 96 h, MTT analysis was performed. Briefly, the culture medium was replaced by 100 µl culture medium containing 1 mg/ml MTT. Following 2 h incubation at 37 °C, MTT-containing medium was removed and 150 µl of dimethylsulfoxide (DMSO) was added to dissolve formazan crystals. Absorbance was measured at 570 nm and background measured at 650 nm, with a plate reader (Paradigm, Molecular Devices). Fig. 2B shows the average absorbance value ($n=3$) of 6 independent metabolic activity analysis 96 h after seeding 4×10^4 SK-OV-3 Luc or SK-OV-3 Luc IP1.

2.5. *in vitro* bioluminescence

A single cell suspension of SK-OV-3 Luc, SK-OV-3 Luc IP1 and SK-OV-3-Luc-IP2 cells were seeded in a 96-well plate in different cell numbers (125, 250, 500, 1000 and 2000 cells per well). Cells were allowed to adhere for 2 h, just before luciferase activity was measured with IVIS (PerkinElmer), 150 µg/ml D-Luciferin, firefly (Perkin-Elmer) was added. Fig. 2C shows the average bioluminescence value of three replicates.

2.6. *in vivo* survival analysis

Animal experiments were conducted in accordance with the local ethics committee (Ghent University Hospital). Immune deficient female Swiss/nu mice were inoculated intraperitoneally with 1×10^6 SK-OV-3-Luc or SK-OV-3-Luc-IP2 cells. Mice were monitored and from the first visual signs of advanced carcinomatosis (decrease in weight or increase in abdominal circumference) the mice had reached their end-point and were sacrificed. Peritoneal organs were embedded in paraffin before standard hematoxylin and eosin (H&E) staining was conducted. Fig. 3A shows H&E staining of the peritoneal tumor implants, B shows comparative survival curves.




Fig. 1. Schematic showing the successive stages of the *in vivo* selection with indication of the different *in vitro* and *in vivo* assays conducted.

2.7. *in vivo* growth curves

Immune deficient female Swiss/nu mice were inoculated intraperitoneally with 1×10^6 , 0.5×10^6 , 0.25×10^6 and 0.1×10^6 SK-OV-3 Luc IP2 cancer cells. Tumor growth was monitored by weekly bioluminescence imaging (BLI). Fig. 4 shows the different growth curves (A) and the bioluminescence images (B).




Fig. 2. (A) Phase-contrast images of SK-OV-3 Luc, SK-OV-3 Luc IP1 and SK-OV-3-Luc-IP2 cultured cell cultured treated culture flasks. (B) Metabolic activity analysis (MTT): the average absorbance value ($n=3$) of 6 independent metabolic activity analysis 96 h after seeding 4×10^4 SK-OV-3 Luc or SK-OV-3 Luc IP1. (C) *in vitro* average bioluminescence ($n=3$) of SK-OV-3 Luc, SK-OV-3 Luc IP1 and SK-OV-3-Luc-IP2 for 125, 250, 500, 1000 and 2000 cells, 2 h after seeding.





Fig. 3. (A) H&E staining's of peritoneal implants at the site of peritoneum, mesentery, pancreas and diaphragm of SK-OV-3 Luc or SK-OV-3 Luc IP2 tumors. (B) Comparative survival curves of mice IP injected with 1×10^6 SK-OV-3 Luc and SK-OV-3 Luc IP2 cells.




Fig. 4. Growth curves (A) and BLI (B) of mice inoculated with 1×10^6 , 0.5×10^6 , 0.25×10^6 or 0.1×10^6 SK-OV-3 Luc IP2 cells ($n=3$).

Acknowledgments

This research was supported by grants from “Stichting tegen Kanker” (2012–217), “Vlaamse Liga tegen Kanker” and Fund for Scientific Research-Flanders. Elly De Vlieghere received a scholarship from IWT (093153). The study sponsors have no role in the design of the study; the collection, analysis and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.dib.2015.12.037>.

References

- 1 E. De Vlieghere, F. Gremontprez, L. Verset, L. Marien, C.J. Jones, B. De Craene, et al., Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells, *Biomaterials* 54 (2015) 148–157.
- 2 H. Cho, T.C. Lai, G.S. Kwon, Poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer, *J. Control Release* 166 (1) (2013) 1–9.
- 3 P.E. Colombo, M. Boustta, S. Poujol, M. Jarlier, F. Bressolle, I. Teulon, et al., Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer, *Gynecol. Oncol.* 122 (3) (2011) 632–640.
- 4 J. Mikula-Pietrasik, P. Sosinska, E. Naumowicz, K. Maksin, H. Piotrowska, A. Wozniak, et al., Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo, *Clin. Exp. Metastas* (2015).
- 5 A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos, W. Shu, D.D. Giri, et al., Genes that mediate breast cancer metastasis to lung, *Nature*. 436 (7050) (2005) 518–524.
- 6 ATCC: The Global Bioresource Center. (<http://www.lgcstandards-atcc.org/Products/All/HTB-77.aspxspecifications>).